The first CAR-T cell therapy was developed and approved by the FDA in 2017 to treat relapsed or refractory B-cell precursor ...

Explore Fate Therapeutics' pipeline, financials, and market position to assess if its 75% drop reflects true value or ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

First Steps warns moviegoers to silence their cell phones, and sees H.E.R.B.I.E. speak for the first time...which isn't quite ...

An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including ...

Patients with primary cutaneous B-cell lymphoma showed a higher risk of developing prostate and hematologic cancers in a ...

New treatment advances are providing a lot of hope, and even a potential cure, for difficult to treat large B-cell lymphoma ...

Researchers at the University of Colorado Anschutz Medical Campus have uncovered a critical, previously underappreciated role ...

Researchers have uncovered a critical, previously underappreciated role for B cells in vaccine protection. Best known for producing antibodies, B cells also guide other immune cells, specifically CD8 ...

Single-cell biology has transformed how we decode cellular heterogeneity, but a new frontier is emerging: understanding what ...

Adoptive Cell Transfer (ACT) includes a class of immunotherapy approaches to treat cancer.  This procedure focuses on a ...